Baseline Characteristics of Participants in the Malmö Preventive Project (n = 1049)
| Trait . | Controls (n = 496) . | Participants With Incident T2DM (n = 204) . | Participants With Incident CAD (n = 384) . |
|---|---|---|---|
| Age, y | 68.7 ± 5.9 | 69.3 ± 5.7 | 70.6 ± 6.3 |
| Women, % | 37.2 | 31.4 | 21.3 |
| BMI, kg/m2 | 26.5 ± 4.2 | 29.2 ± 4.8 | 27.1 ± 4.1 |
| Fasting glucose, mmol/L | 5.4 ± 0.5 | 6.0 ± 0.6 | 5.5 ± 0.6 |
| Systolic blood pressure, mm Hg | 143.7 ± 20 | 149 ± 17 | 150 ± 21 |
| LDL cholesterol, mmol/L | 3.7 ± 0.9 | 3.7 ± 1.0 | 3.9 ± 1.1 |
| HDL cholesterol, mmol/L | 1.4 ± 0.4 | 1.3 ± 0.4 | 1.3 ± 0.4 |
| Triglycerides, mmol/L | 1.2 ± 0.6 | 1.3 ± 0.6 | 1.4 ± 0.7 |
| Antihypertensive treatment, % | 24.6 | 43.6 | 38.9 |
| Current smokers, % | 18.1 | 22.1 | 25.7 |
| Trait . | Controls (n = 496) . | Participants With Incident T2DM (n = 204) . | Participants With Incident CAD (n = 384) . |
|---|---|---|---|
| Age, y | 68.7 ± 5.9 | 69.3 ± 5.7 | 70.6 ± 6.3 |
| Women, % | 37.2 | 31.4 | 21.3 |
| BMI, kg/m2 | 26.5 ± 4.2 | 29.2 ± 4.8 | 27.1 ± 4.1 |
| Fasting glucose, mmol/L | 5.4 ± 0.5 | 6.0 ± 0.6 | 5.5 ± 0.6 |
| Systolic blood pressure, mm Hg | 143.7 ± 20 | 149 ± 17 | 150 ± 21 |
| LDL cholesterol, mmol/L | 3.7 ± 0.9 | 3.7 ± 1.0 | 3.9 ± 1.1 |
| HDL cholesterol, mmol/L | 1.4 ± 0.4 | 1.3 ± 0.4 | 1.3 ± 0.4 |
| Triglycerides, mmol/L | 1.2 ± 0.6 | 1.3 ± 0.6 | 1.4 ± 0.7 |
| Antihypertensive treatment, % | 24.6 | 43.6 | 38.9 |
| Current smokers, % | 18.1 | 22.1 | 25.7 |
Plasma metabolomics was performed in 1049 individuals; 204 developed T2DM, 384 developed CAD, and 496 remained free from disease (controls). Table displays the average of traditional risk factors for CMD in the three groups. Values expressed with plus/minus sign are the mean ± SD.
Baseline Characteristics of Participants in the Malmö Preventive Project (n = 1049)
| Trait . | Controls (n = 496) . | Participants With Incident T2DM (n = 204) . | Participants With Incident CAD (n = 384) . |
|---|---|---|---|
| Age, y | 68.7 ± 5.9 | 69.3 ± 5.7 | 70.6 ± 6.3 |
| Women, % | 37.2 | 31.4 | 21.3 |
| BMI, kg/m2 | 26.5 ± 4.2 | 29.2 ± 4.8 | 27.1 ± 4.1 |
| Fasting glucose, mmol/L | 5.4 ± 0.5 | 6.0 ± 0.6 | 5.5 ± 0.6 |
| Systolic blood pressure, mm Hg | 143.7 ± 20 | 149 ± 17 | 150 ± 21 |
| LDL cholesterol, mmol/L | 3.7 ± 0.9 | 3.7 ± 1.0 | 3.9 ± 1.1 |
| HDL cholesterol, mmol/L | 1.4 ± 0.4 | 1.3 ± 0.4 | 1.3 ± 0.4 |
| Triglycerides, mmol/L | 1.2 ± 0.6 | 1.3 ± 0.6 | 1.4 ± 0.7 |
| Antihypertensive treatment, % | 24.6 | 43.6 | 38.9 |
| Current smokers, % | 18.1 | 22.1 | 25.7 |
| Trait . | Controls (n = 496) . | Participants With Incident T2DM (n = 204) . | Participants With Incident CAD (n = 384) . |
|---|---|---|---|
| Age, y | 68.7 ± 5.9 | 69.3 ± 5.7 | 70.6 ± 6.3 |
| Women, % | 37.2 | 31.4 | 21.3 |
| BMI, kg/m2 | 26.5 ± 4.2 | 29.2 ± 4.8 | 27.1 ± 4.1 |
| Fasting glucose, mmol/L | 5.4 ± 0.5 | 6.0 ± 0.6 | 5.5 ± 0.6 |
| Systolic blood pressure, mm Hg | 143.7 ± 20 | 149 ± 17 | 150 ± 21 |
| LDL cholesterol, mmol/L | 3.7 ± 0.9 | 3.7 ± 1.0 | 3.9 ± 1.1 |
| HDL cholesterol, mmol/L | 1.4 ± 0.4 | 1.3 ± 0.4 | 1.3 ± 0.4 |
| Triglycerides, mmol/L | 1.2 ± 0.6 | 1.3 ± 0.6 | 1.4 ± 0.7 |
| Antihypertensive treatment, % | 24.6 | 43.6 | 38.9 |
| Current smokers, % | 18.1 | 22.1 | 25.7 |
Plasma metabolomics was performed in 1049 individuals; 204 developed T2DM, 384 developed CAD, and 496 remained free from disease (controls). Table displays the average of traditional risk factors for CMD in the three groups. Values expressed with plus/minus sign are the mean ± SD.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
